登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07874464,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC);
入选标准第 2 条
Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody;
排除标准第 3 条
Unresolved toxicity of CTCAE grade >2 from prior chemoradiotherapy;
排除标准第 21 条
Grade ≥2 pneumonitis resulting from prior chemoradiotherapy;
排除标准第 22 条
World Health Organization (WHO) performance status of 0 or 1;
入选标准第 7 条
WHO performance status of 2-4;
排除标准第 16 条
Wild-type EGFR, ALK, and ROS1;
入选标准第 3 条
Any of the following organ or bone marrow impairments: FEV1 <800 mL; Absolute neutrophil count <1.5 × 10⁹/L; Platelet count <100 × 10⁹/L; Hemoglobin <9.0 g/dL; Creatinine clearance <50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin >1.5 times ULN; AST and ALT >2.5 times ULN.
排除标准第 17 条
Mixed small cell and non-small cell lung cancer histology;
排除标准第 2 条
History of another primary malignancy within the past 5 years, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
排除标准第 11 条
Female patients must not be breastfeeding;
入选标准第 8 条
Pregnancy or breastfeeding; or male or female patients of reproductive potential who are not using effective contraception.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07874464,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female patients aged 18-75 years ; Histologically or cytologically confirmed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC); Wild-type EGFR, ALK, and ROS1; No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy; Availability of unstained archival tumor tissue samples sufficient for analysis; Life expectancy of ≥12 weeks; World Health Organization (WHO) performance status of 0 or 1; Female patients must not be breastfeeding; Adequate organ and bone marrow function, meeting all of the following criteria: Forced expiratory volume in 1 second (FEV1) ≥800 mL; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L; Hemoglobin ≥9.0 g/dL; Creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin ≤1.5 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN.排除标准:Exclusion Criteria:
Concurrent participation in another clinical study, unless it is an observational, non-interventional study; Mixed small cell and non-small cell lung cancer histology; Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody; Major surgery within 4 weeks before study entry, excluding procedures for vascular access; Active autoimmune disease or a history of autoimmune disease within the past 2 years; Active inflammatory bowel disease or a history of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; History of primary immunodeficiency; History of organ transplantation requiring immunosuppressive therapy; Uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, cardiac arrhythmia, active peptic ulcer disease or gastritis, or active bleeding disorders; known hepatitis B surface antigen (HBsAg) positivity with HBV DNA >500 IU/mL, hepatitis C, or human immunodeficiency virus (HIV) infection; or psychiatric illness or social circumstances that would limit compliance with study requirements or impair the ability to provide written informed consent; Known history of tuberculosis, except for old, inactive pulmonary tuberculosis; History of another primary malignancy within the past 5 years, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; Pregnancy or breastfeeding; or male or female patients of reproductive potential who are not using effective contraception. Patients meeting any of the following criteria will not proceed to concurrent chemoradiotherapy: Development of distant metastases; Locoregional disease progression that, in the judgment of the radiation oncologist, precludes definitive chemoradiotherapy because normal tissue dose constraints cannot be met; WHO performance status of 2-4; Any of the following organ or bone marrow impairments: FEV1 <800 mL; Absolute neutrophil count <1.5 × 10⁹/L; Platelet count <100 × 10⁹/L; Hemoglobin <9.0 g/dL; Creatinine clearance <50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin >1.5 times ULN; AST and ALT >2.5 times ULN. Patients meeting any of the following criteria will not proceed to consolidation immunotherapy: Disease progression during concurrent chemoradiotherapy; Use of immunosuppressive medication within 28 days before the first dose of dual immunotherapy, except for intranasal or inhaled corticosteroids at physiological doses, or systemic corticosteroids at doses not exceeding 10 mg/day of prednisone or equivalent. Corticosteroids used to manage chemoradiotherapy-related toxicity are permitted; Unresolved toxicity of CTCAE grade >2 from prior chemoradiotherapy; Grade ≥2 pneumonitis resulting from prior chemoradiotherapy; Any previous grade ≥3 immune-related adverse event (irAE), or any unresolved irAE of grade >1.
引自 ClinicalTrials.gov, NCT07874464, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07874464,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。